to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers

Inclusion Criteria: * Male volunteers in the age between 20 and 55 years old * Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data * Body Mass Index (BMI) in the range of 18.5 to 27 kg/m2 * Available for the entire study period * Willing to adhere to protocol requirements and sign a informed consent form Exclusion Criteria: * History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, cardiovascular disease * Clinically significant vital sign * SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 140 mmHg * DBP(Diastolic Blood Pressure) ≤ 60 mmHg or DBP ≥ 100 mmHg * History of surgery except or gastrointestinal disease which might significantly change absorption of medicines * History of clinically significant allergies, including imatinib * Clinical laboratory test values are outside the accepted normal range * AST(ASpartate Transaminase), ALT(ALanine Transaminase)( \> 1.5 times to normal range * Estimated GFR(Glomerular Filtration Rate) \< 80 mL/min * History of caffeine, alcohol, smoking abuse * caffeine \> 4 cups/day * grapefruit juice \> 4 cups/day * smoking \> 20 cigarettes/day * alcohol \> 140g/week * Participated in a previous clinical trial within 3 months prior to dosing * Donated blood within 60 days prior to dosing * Use of prescription only medicine and oriental medicine within the 14 days before dosing or use of non-prescription medicine within the 10 days before dosing * Subjects considered as unsuitable based on medical judgement by investigators